Physician profile
Jonathan S Thomas
NPI 1548424062
$1,300.03
in general payments reported to CMS, 2019-2025
20 companies · $22.61 in 2025
The $22.61 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $60.58 · 2021: $245 · 2022: $606 · 2023: $108 · 2024: $30.68 · 2025: $22.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $161.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $290.57 | 2021-2023 | Vraylar, Qulipta |
| Novo Nordisk INC | $195.21 | 2020-2023 | Rybelsus, Ozempic |
| Mylan Specialty L.P. | $192.03 | 2019-2022 | |
| Dexcom, INC. | $99.60 | 2022-2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $97.27 | 2021-2022 | |
| Glaxosmithkline, LLC. | $70.96 | 2019-2020 | |
| Tris Pharma INC | $53.37 | 2019 | |
| Abbott Laboratories | $45.56 | 2022 | |
| Pfizer INC. | $41.53 | 2019-2022 | |
| Allergan, INC. | $33.72 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.51 | 2021 | |
| Soleno Therapeutics, INC. | $22.61 | 2025 | Vykat Xr |
| Bayer Healthcare Pharmaceuticals INC. | $19.75 | 2022 | |
| Merck Sharp & Dohme LLC | $18.69 | 2022 | |
| Genentech USA, INC. | $18.01 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $16.89 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $15.51 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.69 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.61 | 2023 | Xarelto |
| Innocoll Pharmaceuticals Limited | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.